Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2008

View Archived Issues

New mu opioid receptor ligands disclosed in recent Progenics patent

Recent patents divulge novel agents for endocrine-related disorders

Plethora completes recruitment into European arm of phase III study of PSD-502

Canopus' CB-1400 reduces tumors, works synergistically with other agents in lung cancer models

Eplivanserin doubles slow-wave sleep time in healthy humans

Osteologix reports phase II data on strontium malonate in osteoporosis

Stable disease achieved with ITF-2357 treatment in Hodgkin's lymphoma

Piboserod treatment ameliorates systolic function in patients with chronic heart failure

Leukemia-initiating cells targeted via PML gene

Nile Therapeutics enters license agreement with Mayo Clinic for natriuretic peptide CU-NP

A.P. Pharma completes enrollment in phase III trial of APF-530 in CINV

Auspex patent discloses new antihypertensive agents

Dyax completes patient treatment in second phase III clinical trial of DX-88 in HAE

Stiefel to acquire Barrier Therapeutics

EMEA grants orphan drug status to Lorus Therapeutics' LOR-2040 in AML

FDA grants Genta permission to resume clinical trials of tesetaxel

FDA clears Acrux's phase III pivotal Testosterone MD-Lotion trial

Hawaii Biotech begins phase I trial for West Nile vaccine

Peplin treats first patient in phase IIb PEP-005 trial in actinic keratosis

Tranzyme presents successful thorough QT/QTc study of TZP-101

FDA extends priority review period for GlaxoSmithKline's Promacta

MediciNova initiates phase II MN-221 trial in moderate to severe asthma

The FDA licenses sanofi pasteur's Pentacel five-component pediatric vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...